AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17474807 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day)
Number of subjects: 99
Study 17474807 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-448,187 (3 mg/day)
Number of subjects: 99
Study 17474807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 15632984 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestalt therapy, Rosen Body Work, and Cranio Sacral therapy (2-day course followed by 6-10 individual sessions and a 1-day follow-up course)
Number of subjects: 87
Study 15632984 — intervention group
Group type: COMPARATOR
Intervention: Nontreated control group
Number of subjects: 87
Study 11911170 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intensive care system
Number of subjects: 30
Study 11911170 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 30
Study 9522319 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous transdermal estrogen replacement therapy (50 micrograms 17/beta‐estradiol/day, eight patches/cycle)
Number of subjects: 2459
Study 9522319 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical transdermal estrogen replacement therapy (50 micrograms 17/beta‐estradiol/day, six patches/cycle, 3 weeks on, 1 week off)
Number of subjects: 2459
Study 9522319 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (Continuous and Cyclical)
Number of subjects: 2459
Study 7957543 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ciclotropium intravenous infusion
Number of subjects: 12
Study 3108355 — intervention group
Group type: COMPARATOR
Intervention: Sulpiride (1 mg/kg im) + Placebo (2 ml saline iv)
Number of subjects: 13
Study 3108355 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (1 mg/kg im)
Number of subjects: 13
Study 3108355 — intervention group
Group type: COMPARATOR
Intervention: Sulpiride (1 mg/kg im) + TRH (200 micrograms iv)
Number of subjects: 13
Study 3108355 — intervention group
Group type: COMPARATOR
Intervention: Control standard insulin tolerance test (0.1 U/kg iv)
Number of subjects: 13
Study 30357823 — intervention group
Group type: EXPERIMENTAL
Intervention: COSF 20 mg
Number of subjects: 51
Study 30357823 — intervention group
Group type: COMPARATOR
Intervention: CTAB 20 mg
Number of subjects: 51
Study 30357823 — intervention group
Group type: EXPERIMENTAL
Intervention: COSF 10 mg
Number of subjects: 51
Study 30357823 — intervention group
Group type: COMPARATOR
Intervention: CTAB 10 mg
Number of subjects: 51
Study 30357823 — intervention group
Group type: EXPERIMENTAL
Intervention: COSF 20 mg and COSF 10 mg
Number of subjects: 51
Study 30357823 — intervention group
Group type: EXPERIMENTAL
Intervention: COSF
Number of subjects: 51
Study 27387994 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose edoxaban regimen (HDER) 60/30 mg
Number of subjects: 5973
Study 27387994 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (INR 2.0-3.0)
Number of subjects: 5973
Study 24706498 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 1580
Study 24706498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1580
Study 22859242 — intervention group
Group type: EXPERIMENTAL
Intervention: SkinMedica (SKM) regimen
Number of subjects: 35
Study 22859242 — intervention group
Group type: EXPERIMENTAL
Intervention: Obagi (OMP) regimen
Number of subjects: 35
Study 20839238 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan plus ultra low-dose quinidine (DMq) at 30/10mg (DMq-30)
Number of subjects: 326
Study 20839238 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan plus ultra low-dose quinidine (DMq) at 20/10mg (DMq-20)
Number of subjects: 326
Study 20839238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326
Study 18053310 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/d of dietary secoisolariciresinol diglucoside (SDG) from flaxseed extract
Number of subjects: 55
Study 18053310 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/d of dietary secoisolariciresinol diglucoside (SDG) from flaxseed extract
Number of subjects: 55
Study 18053310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 15746480 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (placebo-controlled study)
Number of subjects: 8
Study 15746480 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 8
Study 12723748 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 84192
Study 12723748 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 84192
Study 12723748 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen and Paracetamol
Number of subjects: 84192
Study 10569170 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification and intraocular lens (IOL) implantation (AcrySof MA30BA)
Number of subjects: 100
Study 10569170 — intervention group
Group type: COMPARATOR
Intervention: Control group (no striae)
Number of subjects: 100
Study 10569170 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification and intraocular lens (IOL) implantation
Number of subjects: 100
Study 8740787 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFp (Cyclophosphamide, Methotrexate, 5-Fluorouracil + low-dose prednisone)
Number of subjects: 491
Study 8740787 — intervention group
Group type: COMPARATOR
Intervention: CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil)
Number of subjects: 491
Study 8740787 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFp
Number of subjects: 491
Study 8740787 — intervention group
Group type: COMPARATOR
Intervention: CMF
Number of subjects: 491
Study 1833897 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (2 x bolus 0.5 mg/kg, infusion 5.0 mcg/kg/min)
Number of subjects: 20
Study 1833897 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (3-4.0 mcg/kg/min)
Number of subjects: 20
Study 1833897 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 20
Study 6884167 — intervention group
Group type: EXPERIMENTAL
Intervention: lactulose (40 g)
Number of subjects: 14
Study 6884167 — intervention group
Group type: EXPERIMENTAL
Intervention: metoclopramide (20 mg tds)
Number of subjects: 14
Study 6884167 — intervention group
Group type: EXPERIMENTAL
Intervention: magnesium sulfate (0.1 g/kg body weight)
Number of subjects: 14
Study 6884167 — intervention group
Group type: COMPARATOR
Intervention: control conditions
Number of subjects: 14
Study 30767052 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel mathematical framework including gene conversion in gene tree/species tree reconciliation
Number of subjects: 0
Study 30767052 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized algorithm for reconciliation
Number of subjects: 0
Study 27461523 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-stabilized rice bran (30 g/day)
Number of subjects: 29
Study 27461523 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked navy bean powder (35 g/day)
Number of subjects: 29
Study 26674998 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 26
Study 26674998 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Father Care (KFC)
Number of subjects: 26
Study 26674998 — intervention group
Group type: COMPARATOR
Intervention: KMC and KFC (comparison between parents)
Number of subjects: 26
Study 25149657 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexion group (knee in 90° flexion)
Number of subjects: 80
Study 25149657 — intervention group
Group type: COMPARATOR
Intervention: Extension group (knee in full extension)
Number of subjects: 80
Study 25149657 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (same postoperative rehabilitation exercises)
Number of subjects: 80
Study 22571836 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with social reinforcement
Number of subjects: 125
Study 22571836 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group without social reinforcement
Number of subjects: 125
Study 22571836 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 125
Study 19852292 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingyi Decoction (QYD)
Number of subjects: 125
Study 19852292 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 125
Study 19852292 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 125
Study 17242078 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (0.01 mg/kg)
Number of subjects: 130
Study 17242078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 15065643 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + Sibutramine 1 x 10 mg/d (n=22)
Number of subjects: 86
Study 15065643 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + Orlistat 3 x 120 mg/d (n=25)
Number of subjects: 86
Study 15065643 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Diet + Sibutramine + Orlistat (n=20)
Number of subjects: 86
Study 15065643 — intervention group
Group type: COMPARATOR
Intervention: Diet (n=19)
Number of subjects: 86
Study 11642485 — intervention group
Group type: EXPERIMENTAL
Intervention: Division of the pedicle at 2 weeks
Number of subjects: 60
Study 11642485 — intervention group
Group type: COMPARATOR
Intervention: Division of the pedicle at 4 weeks
Number of subjects: 60
Study 9876861 — intervention group
Group type: EXPERIMENTAL
Intervention: Single session treatment (SS)
Number of subjects: 111
Study 9876861 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-needed intervention (TAN)
Number of subjects: 111
Study 7994783 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (40 mg/40 ml saline) given within 24 h of TUR and once during the 1st week, weekly for 4 weeks and then monthly for 11 months
Number of subjects: 135
Study 2689017 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate cream (Dermovate) with occlusion using Comfeel Coloplast dressing
Number of subjects: 10
Study 2689017 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate cream (Dermovate) without occlusion
Number of subjects: 10
Study 2689017 — intervention group
Group type: COMPARATOR
Intervention: Untreated skin
Number of subjects: 10
Study 791319 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 791319 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 0
Study 791319 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and Pindolol
Number of subjects: 0
Study 29348183 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing 60% oxygen during constant-load cycling
Number of subjects: 14
Study 29348183 — intervention group
Group type: COMPARATOR
Intervention: Room air during constant-load cycling
Number of subjects: 14
Study 29348183 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental cycling tests
Number of subjects: 14
Study 27912875 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile (1500mg, 500mg capsule 3 times daily)
Number of subjects: 179
Study 27912875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 27912875 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile
Number of subjects: 179
Study 24462735 — intervention group
Group type: COMPARATOR
Intervention: TDF + placebo (300 mg TDF)
Number of subjects: 126
Study 24462735 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF + emtricitabine (300 mg TDF + 200 mg emtricitabine)
Number of subjects: 126
Study 22196945 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended nevirapine prophylaxis
Number of subjects: 1527
Study 22196945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1527
Study 22196945 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended nevirapine
Number of subjects: 1527
Study 21122701 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g/d of an insoluble fraction of partially hydrolyzed soy protein (SP)
Number of subjects: 0
Study 21122701 — intervention group
Group type: COMPARATOR
Intervention: 25 g/d total milk proteins (TMP)
Number of subjects: 0
Study 18294814 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone treatment
Number of subjects: 48
Study 18294814 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine treatment
Number of subjects: 48
Study 18294814 — intervention group
Group type: COMPARATOR
Intervention: Untreated heroin addicts
Number of subjects: 48
Study 18294814 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 48
Study 16796928 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery perfusion with hypothermic washed red blood cell solution during CPB
Number of subjects: 30
Study 16796928 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 14636805 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention schools
Number of subjects: 1704
Study 14636805 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 1704
Study 11126231 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified cognitive-behavioural treatment (M-CBT)
Number of subjects: 63
Study 11126231 — intervention group
Group type: COMPARATOR
Intervention: Standard cognitive-behavioural therapy (S-CBT)
Number of subjects: 63
Study 11126231 — intervention group
Group type: EXPERIMENTAL
Intervention: Both M-CBT and S-CBT
Number of subjects: 63
Study 8816537 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiography
Number of subjects: 79
Study 8816537 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective stent placement based on angiographic criteria
Number of subjects: 79
Study 8816537 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and post-PTA angiograms
Number of subjects: 79
Study 8816537 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage stenosis and pressure gradient correlation
Number of subjects: 79
Study 2062772 — intervention group
Group type: EXPERIMENTAL
Intervention: urapidil (30 mg twice daily)
Number of subjects: 10
Study 2062772 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 6134136 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg/day)
Number of subjects: 6
Study 6134136 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 6
Study 30664490 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based sexual health influencers (SHIs)
Number of subjects: 1031
Study 30664490 — intervention group
Group type: COMPARATOR
Intervention: Non-influencers
Number of subjects: 1031
Study 29522549 — intervention group
Group type: EXPERIMENTAL
Intervention: Secure subliminal priming
Number of subjects: 0
Study 29522549 — intervention group
Group type: COMPARATOR
Intervention: Neutral subliminal priming
Number of subjects: 0
Study 26658817 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT)
Number of subjects: 52
Study 26658817 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 52
Study 25248497 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus WWWT (What Were We Thinking) intervention
Number of subjects: 368
Study 25248497 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 368
Study 22360337 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanosome vitamin C iontophoresis
Number of subjects: 14
Study 22360337 — intervention group
Group type: COMPARATOR
Intervention: Glycolic acid 70% peel
Number of subjects: 14
Study 20359693 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Behavioral Individual Treatment (ABIT)
Number of subjects: 102
Study 20359693 — intervention group
Group type: COMPARATOR
Intervention: Alcohol Behavioral Couples Treatment (ABCT)
Number of subjects: 102
Study 17957149 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous pramlintide injection (5 microg/unit of insulin)
Number of subjects: 8
Study 17957149 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous pramlintide infusion (5 microg/unit of insulin over 120 min)
Number of subjects: 8
Study 17957149 — intervention group
Group type: COMPARATOR
Intervention: Insulin-only administration
Number of subjects: 8
Study 15750043 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing at 7 beats/minute faster than the mean nocturnal heart rate
Number of subjects: 20
Study 15750043 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing at 15 beats/minute faster than the mean nocturnal heart rate
Number of subjects: 20
Study 15750043 — intervention group
Group type: COMPARATOR
Intervention: Nonpacing
Number of subjects: 20
Study 12019280 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodynamic (HD) measurements and a predefined algorithm
Number of subjects: 104
Study 12019280 — intervention group
Group type: COMPARATOR
Intervention: Specialist care (SC)
Number of subjects: 104
Study 10535231 — intervention group
Group type: EXPERIMENTAL
Intervention: PATHS (Promoting Alternative THinking Strategies) curriculum and teacher consultation delivered by Grade 1 teachers, 57 lessons focused on self‐control, emotional awareness, peer relations, and problem solving.
Number of subjects: 378
Study 10535231 — intervention group
Group type: EXPERIMENTAL
Intervention: PATHS (Promoting Alternative THinking Strategies) curriculum and teacher consultation delivered by Grade 1 teachers.
Number of subjects: 378
Study 10535231 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of implementation of the PATHS curriculum.
Number of subjects: 378
Study 10535231 — intervention group
Group type: COMPARATOR
Intervention: Comparison classrooms (control group).
Number of subjects: 378
Study 7852517 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX) 50 mg
Number of subjects: 6
Study 1971034 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase (100 mg intravenous plus heparin)
Number of subjects: 5013
Study 1971034 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus heparin
Number of subjects: 5013
Study 399767 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified activities of daily living (ADL) index
Number of subjects: 0
Study 399767 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital ADL scores
Number of subjects: 0
Study 399767 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital scores vs. patients' own estimates
Number of subjects: 0
Study 399767 — intervention group
Group type: EXPERIMENTAL
Intervention: Scores obtained in hospital vs. at home
Number of subjects: 0
Study 399767 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer variability
Number of subjects: 0
Study 399767 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term within-patient variability
Number of subjects: 0
Study 31997417 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of health insurance
Number of subjects: 905
Study 31997417 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor self-rated general health
Number of subjects: 905
Study 31997417 — intervention group
Group type: EXPERIMENTAL
Intervention: Average self-rated general health
Number of subjects: 905
Study 31997417 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotony of diet
Number of subjects: 905
Study 31997417 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of dentures
Number of subjects: 905
Study 31997417 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufficient dentures
Number of subjects: 905
Study 31997417 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of dentures
Number of subjects: 905
Study 31997417 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 905
Study 30321764 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclin D1 overexpression in carcinomas and non-tumour epithelia
Number of subjects: 54
Study 30321764 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclin D1 overexpression in different epithelial layers
Number of subjects: 54
Study 30321764 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear expressions of cyclin D1 and Ki-67 in the basal layer of distant epithelium
Number of subjects: 54
Study 29171818 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab quarterly (675 mg at baseline, placebo at weeks 4 and 8)
Number of subjects: 1130
Study 29171818 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab monthly (675 mg at baseline, 225 mg at weeks 4 and 8)
Number of subjects: 1130
Study 29171818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1130
Study 25604727 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum R0071
Number of subjects: 581
Study 25604727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 581
Study 23433257 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol suspension (1 drop)
Number of subjects: 122
Study 23433257 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol gel (1 application)
Number of subjects: 122
Study 23433257 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin suspension (1 drop)
Number of subjects: 122
Study 23433257 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin suspension (1 drop)
Number of subjects: 122
Study 23433257 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol suspension (repeated instillations every 10 min for a total of 4 drops)
Number of subjects: 122
Study 23433257 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol gel (repeated instillations every 10 min for a total of 4 drops)
Number of subjects: 122
Study 21297503 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine-based regimen
Number of subjects: 19257
Study 21297503 — intervention group
Group type: COMPARATOR
Intervention: Atenolol-based regimen
Number of subjects: 19257
Study 19330661 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-assisted learning (PAL) programme with 10 patient-centred tutorials led by final year tutors over a 5-week ward placement.
Number of subjects: 168
Study 19330661 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) did not participate in the PAL programme.
Number of subjects: 168
Study 16730318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) intervention, weekly sessions over 6 weeks
Number of subjects: 32
Study 16730318 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32